Placeholder

Creating Value through Personalized Medicine

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

SKU: 1702. Categories: , .

Product Description

The era of traditional blockbuster pharmaceutical products, experts agree, is probably gone. Companies will have to develop a new model for success, one that focuses on targeted therapies for those patients most likely to respond. This will require all stakeholders — bio/pharmaceutical companies, device manufacturers, regulators, policymakers, physicians, consumers, payers, and partners — to work together in a way previously not seen and share information about biomarkers, genomic data, predictive toxicology, and serious adverse events.
Those bio/pharmaceutical companies that are willing to take the risk to adopt a personalized medicine strategy will be the ones that succeed in the future. While the risk that personalized medicine will stratify patients and markets is very real, so too is the value such products will provide to pharmaceutical companies and their…

Sidebar:
Benefits of Personalized Medicine
The Market for Biomarkers
Key Terms
Stakeholder Implications
Personalized Medicine in Action

Experts on this topic
Vijay Aggarwal, Ph.D. CEO, Aureon Laboratories, a life-sciences company that provides tools dedicated to enabling the advancement of predictive and personalized cancer treatment. For more information, visit aureon.com.
Stan Bernard, M.D. President, Bernard Associates LLC, a pharmaceutical and healthcare management consulting firm. For more information, visit bernardassociatesllc.com. Dr. Bernard can be reached at sbernardmd@bernardassociatesllc.com.
LingSing Chen, Ph.D. VP of Translational Medicine Research, QPS, a global GLP/GCP-compliant contract research laboratory supporting drug discovery and development. For more information, visit qps-usa.com.
Anthony T. Everhart, M.D. Director, Medical Monitoring, Americas, Chiltern, a global contract research organization with experience conducting and staffing international Phase I to Phase IV clinical trials. For more information, visit chiltern.com. Dr. Everhart can be reached at todd.everhart@chiltern.com.
Gary Kurtzman, M.D. Managing Director in the Life Sciences Group, Safeguard Scientifics Inc., which provides capital, as well as a range of strategic, operational, and management resources. For more information, visit safeguard.com. Dr. Kurtzman can be reached at gkurtzman@safeguard.com.
Husseini K. Manji, M.D. VP, CNS and Pain, Johnson & Johnson Pharmaceutical Research & Development, which brings innovative ideas, products, and services to advance the health and well-being of people. For more information, visit jnjpharmarnd.com.
Thomas Metcalfe. Head, Personalized Healthcare Portfolio, Roche, which provides innovative products and services that address prevention, diagnosis, and treatment of diseases. For more information, visit roche.com.
Alan Minsk. Partner and Leader of the Food & Drug Practice, Arnall Golden Gregory LLP, a law firm. For more information, visit agg.com. Mr. Minsk can be reached at alan.minsk@agg.com.
Raaj Trivedi. VP of Marketing, Clarient Inc., which provides technologies and services for the characterization, assessment, and treatment of cancer. For more information, visit clarientinc.com. Mr. Trivedi can be reached at rtrivedi@clarientinc.com.
Vance Vanier, M.D. Chief Medical Officer, Navigenics, a personal genomics testing company. For more information, visit navigenics.com.

FEEDBACK